Dr. Hamzavi is among three board-certified dermatologists trained to perform MKTP. They use the same technique developed by MKTP pioneer Sanjeev Mulekar, M.D., of the National Vitiligo Center in Saudi Arabia.
MKTP is among multiple treatment options available at Henry Ford for treating vitiligo, which currently has no cure. These include topical medications, light therapy, depigmentation and skin grafting. Ideal candidates for MKTP are adults and children whose vitiligo patches have not increased in size and no new patches formed in at least six months.
The results of Henry Ford's research study, published online in August in the Journal of the American Academy of Dermatology, illustrate the potential of MKTP as a viable treatment option. Twenty-three patients regained on average 45 percent of their natural skin color. Ten patients with a specific type of vitiligo regained on average 65 percent of their skin color.
Dr. Hamzavi also says MKTP is "well-suited" for treating patients with burn-related injuries.
"MKTP provides a pigment reservoir where there is none and burn patients are ideal for this surgery because their immune system will not reject the transplanted skin cells," he says.
During MKTP, melanocyte cells, which produce pigment in the skin, hair and eyes, are harvested from an area of healthy skin and separated to make a skin cell mixture. This mixture then is applied to the treatment area and covered with a specially developed adhesive biologic dressing. MKTP allows dermatologists to treat the affected area up to 10 times the area of donor skin, Dr. Hamzavi says.
|Contact: David Olejarz|
Henry Ford Health System